Department of Cardiology, Health Sciences University, Bağcılar Training and Research Hospital, İstanbul, Turkey.
Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2425-2434. doi: 10.26355/eurrev_202103_25284.
The primary objective of this study was to evaluate the frequency and impact of acute myocardial injury on prognosis in hospitalized COVID-19 patients.
This was a retrospective study that included consecutive hospitalized patients with COVID-19. Clinic-demographic characteristics, laboratory values, and high-sensitivity troponin I were extracted from the electronic database. Mortality and other clinical complications, including respiratory failure requiring invasive mechanical ventilation and acute kidney injury were recorded. Myocardial injury was defined as having a serum troponin I value >19.8 ng/mL. We performed Kaplan-Meier survival analysis and Cox regression to determine survival times and independent predictors of mortality.
A total of 324 patients were included. Seventy-seven patients (23.8%) had acute myocardial injury. The primary outcome measure, namely death, occurred in 54.5% and 3.2% of the patients with and without myocardial injury, respectively. Notably, 75.3% of the patients with myocardial injury and 6.5% of the patients without myocardial injury developed ARDS. Overall, 50 out of 324 patients (15.4%) died during the study period. The mortality rate was 54.5% in patients with myocardial injury and 3.2% in patients without myocardial injury. Mean survival times were significantly different between the groups (15.1±0.9 days in patients with myocardial injury and 24.4±0.7 days in patients without myocardial injury, log-rank test p-value <0.001).
The presence of chronic kidney disease and application of invasive mechanical ventilation were found to be independent predictors of in-hospital mortality. The presence of acute myocardial injury was common but not independently associated with mortality among hospitalized COVID-19 patients.
本研究的主要目的是评估住院 COVID-19 患者中急性心肌损伤的频率及其对预后的影响。
这是一项回顾性研究,纳入了连续住院的 COVID-19 患者。从电子数据库中提取临床-人口统计学特征、实验室值和高敏肌钙蛋白 I。记录死亡率和其他临床并发症,包括需要有创机械通气的呼吸衰竭和急性肾损伤。心肌损伤定义为血清肌钙蛋白 I 值>19.8ng/ml。我们进行 Kaplan-Meier 生存分析和 Cox 回归分析,以确定生存时间和死亡率的独立预测因素。
共纳入 324 例患者。77 例(23.8%)发生急性心肌损伤。主要结局指标即死亡分别发生在有心肌损伤和无心肌损伤的患者中,占 54.5%和 3.2%。值得注意的是,75.3%有心肌损伤的患者和 6.5%无心肌损伤的患者发生了急性呼吸窘迫综合征。总的来说,在研究期间,324 例患者中有 50 例(15.4%)死亡。有心肌损伤的患者死亡率为 54.5%,无心肌损伤的患者死亡率为 3.2%。两组间的平均生存时间差异有统计学意义(心肌损伤组为 15.1±0.9 天,无心肌损伤组为 24.4±0.7 天,log-rank 检验 p 值<0.001)。
慢性肾脏病的存在和有创机械通气的应用被发现是住院 COVID-19 患者院内死亡率的独立预测因素。急性心肌损伤在住院 COVID-19 患者中很常见,但与死亡率无关。